We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
MabCure Inc (CE) | USOTC:MBCI | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 20, 2012
MABCURE INC.
(Exact name
of registrant as specified in its charter)
Nevada
(State or other jurisdiction
of incorporation)
333-141131
(Commission File Number)
20-4907813
(IRS Employer
Identification No.)
21 Sparrow Circle
White Plains, NY
10605
(Address of principal executive offices and Zip
Code)
(845) 591-3144
(Registrant's
telephone number, including area code)
228 Park Ave S #15740
New York, NY 10003
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 5.02 | Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers |
On September 20, 2012, the Board of Directors of the Company provided Amnon Gonenne, the Company's President and Chief Executive Officer, with ninety (90) days prior written notice of termination from his position as President and CEO of the Company. Mr. Gonenne will continue to serve as a member of the Company's Board of Directors.
On September 11, 2012, Mr. Charles Tackney, the Company's Chief Scientific Officer, informed the Company that he was resigning from his position as CSO, effective in ninety days. Mr. Tackney's resignation is for personal reasons, and is not the result of any disagreement with the Company relating to the Companys operations, policies, or practices.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MABCURE
INC.
(Registrant)
By: | /s/ David Frank | ||
/s/ Vered Caplan | |||
Members of the Board of Registrant |
Date: September 20, 2012
1 Year MabCure (CE) Chart |
1 Month MabCure (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions